GAITHERSBURG, Md., May 17 (UPI) -- A U.S. Food and Drug Administration panel Wednesday unanimously endorsed Novartis' Exelon to treat Parkinson's-related dementia.
The panel voted 8 to 0 that the drug is safe for use in treating dementia associated with the debilitating disease of the nervous system.
Advertisement
Exelon was approved in 2000 to treat Alzheimer's disease.
The FDA is not bound to follow its expert panels' advice but does so in most cases.
The panel's strong endorsement for Exelon's expanded use was based on the fact that no serious safety problems were seen in Exelon's nearly six years on the market.
